May 6, 2013
| Alexandra Mulvey
Today, many up-and-coming CD antigens are joining the classics as promising targets for immune-based drug development as part of a new class of treatment that directly targets immune cell co-stimulatory pathways to boost the immune response against cancer. And many “remixes” have brought the classics in vogue once again.
breast cancer, CD antigens, clinical accelerator, kidney cancer, leukemia, lloyd old, lung cancer, lymphoma, melanoma, ovarian cancer